The transition of a pharmaceutical product from a patent-protected brand-name drug to a competitive generic is a cornerstone of modern

In pharmaceutical development, where a single patent can underpin a franchise worth tens of billions of dollars, the concept of

This report is designed for the strategic executive and the savvy in-house counsel. It’s a guide to moving beyond the

In the pharmaceutical industry value is created not just in the laboratory but on the complex chessboard of international trade

Let’s be candid. The era of the single-modality blockbuster, the “one-pill-fits-all” small molecule or the “one-target” monoclonal antibody, is drawing

The Multi-Trillion-Dollar Pivot If you are an IP strategist, a business development leader, or an R&D chief in the pharmaceutical

Introduction: The High-Stakes Game of Pharmaceutical Lifecycles The lifecycle of a drug is a story of immense investment, groundbreaking science,

The intellectual property landscape for small molecule pharmaceuticals has never been more challenging or critical. As R&D costs soar and